George Magrath Purchases 90,294 Shares of Opus Genetics, Inc. (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) CEO George Magrath purchased 90,294 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was bought at an average cost of $1.01 per share, for a total transaction of $91,196.94. Following the completion of the acquisition, the chief executive officer now directly owns 483,244 shares of the company’s stock, valued at $488,076.44. This represents a 22.98 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

George Magrath also recently made the following trade(s):

• On Monday, November 18th, George Magrath bought 9,706 shares of Opus Genetics stock. The stock was acquired at an average price of $1.02 per share, with a total value of $9,900.12.

Opus Genetics Stock Up 10.9 %

Shares of NASDAQ IRD opened at $0.98 on Thursday. Opus Genetics, Inc. has a 52 week low of $0.85 and a 52 week high of $3.40.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.01. The business had revenue of $3.87 million for the quarter, compared to analysts’ expectations of $1.17 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. On average, research analysts anticipate that Opus Genetics, Inc. will post -1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright initiated coverage on shares of Opus Genetics in a research report on Wednesday, November 13th. They set a “buy” rating and a $8.00 target price on the stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.